Structure and Function of Heparin Cofactor II
肝素辅因子 II 的结构和功能
基本信息
- 批准号:6904656
- 负责人:
- 金额:$ 49.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-05-01 至 2006-06-30
- 项目状态:已结题
- 来源:
- 关键词:antithrombinsatherosclerosisblood proteinscarbohydrate structureclinical researchcofactorembryonic stem cellenzyme activityenzyme inhibitorsenzyme structuregenetically modified animalshemostasisheparinhuman subjectimmunocytochemistrylaboratory mousemucopolysaccharidesmutantprotein protein interactionprotein structure functionsynthetic peptidethrombin
项目摘要
DESCRIPTION (provided by applicant): The long-term goal of this project is to elucidate the mechanism of action and physiologic function of heparin cofactor H (HCII). HCII is an inhibitor of thrombin that is present in plasma at a concentration of -1 uM. The anticoagulant activity of HCII is greatly increased by heparin or dermatan sulfate, and dermatan sulfate proteoglycans on the surface of fibroblasts and smooth muscle cells stimulate HCH. Previously, cDNA and genomic clones for human and murine HCII were isolated, recombinant HCII was expressed in E. coli, site-directed mutagenesis was performed to identify important amino acid residues that interact with thrombin and glycosaminoglycans, and the structure of a high-affinity hexasaccharide that binds HCII in porcine skin dermatan sulfate was identified. Although the function of HCII in vivo remains unknown, indirect evidence suggests that HCII activity increases during pregnancy and perhaps serves to inhibit coagulation of maternal blood in the placenta. In addition, the presence of HCII in the intima of normal human arteries and the altered composition of dermatan sulfate (with reduced HCII-stimulating activity) in atherosclerotic lesions provide circumstantial evidence of a role for HCII in atherogenesis. By means of targeted gene disruption in embryonic stem cells, a murine model of HCII deficiency has been developed. The following specific aims are proposed: (1) Determine the effects of HCII deficiency on hemostasis, atherogenesis, wound repair, and inflammation in the mouse. (2) Determine the location of endogenous HCH in human and murine tissues by immunohistochemical methods and identify binding Sites for exogenous HCII in tissue sections. (3) Characterize the oligosaccharide structures in glycosaminoglycans derived from placenta and other tissues that are required for interaction with HCII. (4) Determine the prevalence of HCII deficiency in patients with atherosclerosis. New information about the structure, mechanism of action, and function of HCII in vivo will provide a better understanding of the regulation of thrombin activity under normal and pathologic conditions.
描述(申请人提供):本项目的长期目标是阐明肝素辅因子H(HCII)的作用机制和生理功能。HCII是一种凝血酶抑制物,以-1微米的浓度存在于血浆中。肝素或硫酸皮肤素可显著增强HCII的抗凝血活性,而成纤维细胞和平滑肌细胞表面的硫酸皮肤素蛋白多糖刺激HCH。在此之前,我们分离了人和小鼠HCII的cDNA和基因组克隆,在大肠杆菌中表达了重组的HCII,通过定点突变鉴定了与凝血酶和糖胺聚糖相互作用的重要氨基酸残基,并鉴定了猪皮肤硫酸皮肤素中与HCII结合的高亲和力六糖的结构。虽然HCII在体内的功能尚不清楚,但间接证据表明,HCII活性在怀孕期间增加,可能有助于抑制母体血液在胎盘中的凝结。此外,正常人动脉内膜中HCII的存在和动脉粥样硬化病变中硫酸皮肤素成分的改变(HCII刺激活性降低)提供了HCII在动脉粥样硬化形成中作用的间接证据。通过在胚胎干细胞中进行靶向基因破坏,已经建立了小鼠HCII缺乏症模型。提出了以下具体目标:(1)确定HCII缺乏对小鼠止血、动脉粥样硬化、伤口修复和炎症的影响。(2)用免疫组织化学方法确定内源性六氯环己烷在人和小鼠组织中的定位,并在组织切片中确定外源性六氯环己烷的结合部位。(3)鉴定胎盘和其他组织中与HCII相互作用所需的糖胺聚糖的寡糖结构。(4)测定动脉粥样硬化患者HCII缺乏症的患病率。有关体内HCII的结构、作用机制和功能的新信息将有助于更好地理解正常和病理条件下凝血酶活性的调节。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DOUGLAS M TOLLEFSEN其他文献
DOUGLAS M TOLLEFSEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DOUGLAS M TOLLEFSEN', 18)}}的其他基金
Antithrombotic Activity of Ascidian Glycosaminoglycans
海鞘糖胺聚糖的抗血栓活性
- 批准号:
6622188 - 财政年份:2002
- 资助金额:
$ 49.94万 - 项目类别:
Antithrombotic Activity of Ascidian Glycosaminoglycans
海鞘糖胺聚糖的抗血栓活性
- 批准号:
6441300 - 财政年份:2002
- 资助金额:
$ 49.94万 - 项目类别:
Antithrombotic Activity of Ascidian Glycosaminoglycans
海鞘糖胺聚糖的抗血栓活性
- 批准号:
6696337 - 财政年份:2002
- 资助金额:
$ 49.94万 - 项目类别:
Structure and Function of Heparin Cofactor II
肝素辅因子 II 的结构和功能
- 批准号:
7649349 - 财政年份:1996
- 资助金额:
$ 49.94万 - 项目类别:
Structure and Function of Heparin Cofactor II
肝素辅因子 II 的结构和功能
- 批准号:
6763078 - 财政年份:1996
- 资助金额:
$ 49.94万 - 项目类别:
STRUCTURE AND FUNCTION OF HEPARIN COFACTOR II
肝素辅因子 II 的结构和功能
- 批准号:
2415676 - 财政年份:1996
- 资助金额:
$ 49.94万 - 项目类别:
Structure and Function of Heparin Cofactor II
肝素辅因子 II 的结构和功能
- 批准号:
6616222 - 财政年份:1996
- 资助金额:
$ 49.94万 - 项目类别:
STRUCTURE AND FUNCTION OF HEPARIN COFACTOR II
肝素辅因子 II 的结构和功能
- 批准号:
2234112 - 财政年份:1996
- 资助金额:
$ 49.94万 - 项目类别:
Structure and Function of Heparin Cofactor II
肝素辅因子 II 的结构和功能
- 批准号:
7143559 - 财政年份:1996
- 资助金额:
$ 49.94万 - 项目类别:
Structure and Function of Heparin Cofactor II
肝素辅因子 II 的结构和功能
- 批准号:
6543596 - 财政年份:1996
- 资助金额:
$ 49.94万 - 项目类别:
相似国自然基金
卡路里限制的T细胞糖脂代谢重塑机制及网络调控
- 批准号:91957111
- 批准年份:2019
- 资助金额:80.0 万元
- 项目类别:重大研究计划
高尿酸血症促进动脉粥样硬化机制探讨
- 批准号:81170251
- 批准年份:2011
- 资助金额:14.0 万元
- 项目类别:面上项目
大麻素CB2受体:巨噬细胞efferocytosis功能调控和不稳定斑块防治的新靶点
- 批准号:81000086
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
磷脂转运蛋白通过磷酸鞘氨醇1影响高密度脂蛋白抗动脉粥样硬化功能的分子机制
- 批准号:81070247
- 批准年份:2010
- 资助金额:33.0 万元
- 项目类别:面上项目
抑制PI3K/Akt/mTOR/p70S6K 信号通路促进巨噬细胞自体吞噬稳定易损斑块的分子机制研究
- 批准号:30971216
- 批准年份:2009
- 资助金额:31.0 万元
- 项目类别:面上项目
基因缺失突变抑制白细胞趋化稳定动脉粥样硬化易损斑块的研究
- 批准号:30871040
- 批准年份:2008
- 资助金额:32.0 万元
- 项目类别:面上项目
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 49.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Contribution of Endothelial Planar Cell Polarity pathways in Blood Flow Direction Sensing
内皮平面细胞极性通路在血流方向传感中的贡献
- 批准号:
10750690 - 财政年份:2024
- 资助金额:
$ 49.94万 - 项目类别:
Colchicine for the prevention of vascular events after an acute intracerebral hemorrhage (CoVasc-ICH)
秋水仙碱用于预防急性脑出血后血管事件(CoVasc-ICH)
- 批准号:
485530 - 财政年份:2023
- 资助金额:
$ 49.94万 - 项目类别:
Operating Grants
Identifying the Role of Sex Hormones in Carotid Atherosclerotic Plaque Instability
确定性激素在颈动脉粥样硬化斑块不稳定中的作用
- 批准号:
494557 - 财政年份:2023
- 资助金额:
$ 49.94万 - 项目类别:
Operating Grants
The Epigenetic Regulator Prdm16 Controls Smooth Muscle Phenotypic Modulation and Atherosclerosis Risk
表观遗传调节因子 Prdm16 控制平滑肌表型调节和动脉粥样硬化风险
- 批准号:
10537602 - 财政年份:2023
- 资助金额:
$ 49.94万 - 项目类别:
Targeted multimodal stimuli-responsive nanogels for atherosclerosis imaging and therapy
用于动脉粥样硬化成像和治疗的靶向多模式刺激响应纳米凝胶
- 批准号:
2880683 - 财政年份:2023
- 资助金额:
$ 49.94万 - 项目类别:
Studentship
Body composition and atherosclerosis-related biomarkers in women with endometriosis
子宫内膜异位症女性的身体成分和动脉粥样硬化相关生物标志物
- 批准号:
23K15842 - 财政年份:2023
- 资助金额:
$ 49.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Regulation of Vascular Calcification by Adventitial Endothelial Cells
外膜内皮细胞对血管钙化的调节
- 批准号:
10642619 - 财政年份:2023
- 资助金额:
$ 49.94万 - 项目类别:
Advancing Student Potential for Inclusion with Research Experiences (ASPIRE)
通过研究经验提升学生融入的潜力(ASPIRE)
- 批准号:
10678356 - 财政年份:2023
- 资助金额:
$ 49.94万 - 项目类别: